G. El Hachem MD

Highlights in gynecological cancers

SUMMARY

ESMO 2024 again yielded a wealth of information regarding gynaecological cancers. Here, the key findings of the latest clinical trials in this field are discussed.

(BELG J MED ONCOL 2024;18(8):325–331)

Highlights in gynaecological cancers

After last year’s ESMO meeting in Munich, the recent ESMO Congress in Barcelona again proved to be a ‘grand cru’ in gynaecological cancer, with the confirmation of the role of maintenance therapy with PARP inhibitors in first-line therapy of advanced ovarian cancer, even beyond BRCA mutation. Additionally, recent progress in the management of endometrial and cervical cancer will be highlighted in this overview.

Triple-negative breast cancer: current treatment and future perspectives

SUMMARY

Triple-negative breast cancer is a heterogeneous subtype of breast carcinoma lacking the expression of oestrogen, progesterone and human epidermal growth factor 2 receptors. For many decades, cytotoxic chemotherapy has been the standard of care offering only a short-living disease control. Knowing its poor outcome and aggressive behaviour, researchers are trying to find new therapeutic options hoping to improve the survival of this population. Many cytotoxic and targeted therapies were tested without major benefit. However, in the era of molecular and mutational classification of tumours, as well as the immune mediated mechanisms of proliferation and progression, the trials are currently oriented towards the identification of potential targets in the tumoral heterogenic environment. Here, we present a review of literature concerning the potential anti-neoplastic options and novel therapies for metastatic triple-negative breast cancers: new cytotoxic agents, new targeted therapies, anti-angiogenic agents, antibody-drug conjugates, poly-ADP ribose transferase inhibitors and immunotherapy. Many agents are promising, yet not powerful enough to get approvals for use into clinical practice.

(BELG J MED ONCOL 2019;13(3):84–92)

P.09 BRAIN METASTASIS: AN UNUSUAL DISSEMINATION OF EXTRA-OSSEOUS EWING SARCOMA

P.12 PRIMARY OVARIAN CARCINOMA: AN UNUSUAL EXTRA-MAMMARY TUMOR METASTASIZING TO THE BREAST: A RETROSPECTIVE ANALYSIS

P.19 A-105 WHEN DRUG TOXICITIES ARE DRIVEN BY SOCIAL HABITS: A CASE REPORT

Highlights in gynaecological cancer

With more than 24,000 attendees, ESMO 2017 was the biggest oncology meeting ever organised in Europe. In the gynaecological cancer domain, there were some potentially practice-changing presentations in ovarian and cervical cancer, whereas new data in endometrial cancer were very sparse.

(BELG J ONCOL 2017;11(7):301–308)